ScinoPharm Taiwan Ltd
TWSE:1789

Watchlist Manager
ScinoPharm Taiwan Ltd Logo
ScinoPharm Taiwan Ltd
TWSE:1789
Watchlist
Price: 23 TWD -1.29% Market Closed
Market Cap: 18.2B TWD
Have any thoughts about
ScinoPharm Taiwan Ltd?
Write Note

ScinoPharm Taiwan Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ScinoPharm Taiwan Ltd
Cost of Revenue Peer Comparison

Comparables:
Y
3705
4746
S
4119
1795
1720

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
ScinoPharm Taiwan Ltd
TWSE:1789
Cost of Revenue
-NT$2.1B
CAGR 3-Years
-8%
CAGR 5-Years
-5%
CAGR 10-Years
3%
Y
YungShin Global Holding Corp
TWSE:3705
Cost of Revenue
-NT$4.2B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
-3%
Formosa Laboratories Inc
TWSE:4746
Cost of Revenue
-NT$2.6B
CAGR 3-Years
-6%
CAGR 5-Years
-7%
CAGR 10-Years
-2%
S
SCI Pharmtech Inc
TWSE:4119
Cost of Revenue
-NT$904.5m
CAGR 3-Years
4%
CAGR 5-Years
7%
CAGR 10-Years
1%
Lotus Pharmaceutical Co Ltd
TWSE:1795
Cost of Revenue
-NT$7.7B
CAGR 3-Years
-2%
CAGR 5-Years
-15%
CAGR 10-Years
-24%
Standard Chem & Pharm Co Ltd
TWSE:1720
Cost of Revenue
-NT$3.7B
CAGR 3-Years
-15%
CAGR 5-Years
-12%
CAGR 10-Years
-8%

See Also

What is ScinoPharm Taiwan Ltd's Cost of Revenue?
Cost of Revenue
-2.1B TWD

Based on the financial report for Jun 30, 2024, ScinoPharm Taiwan Ltd's Cost of Revenue amounts to -2.1B TWD.

What is ScinoPharm Taiwan Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
3%

Over the last year, the Cost of Revenue growth was -5%. The average annual Cost of Revenue growth rates for ScinoPharm Taiwan Ltd have been -8% over the past three years , -5% over the past five years , and 3% over the past ten years .

Back to Top